Recruiting

Glucocorticoids & Methotrexate

Sponsor:

Meyer Children's Hospital IRCCS

Code:

NCT07348263

Conditions

Eosinophilic Fasciitis

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.

Conditions

Eosinophilic Fasciitis

Study ID

NCT07348263

Start date

May 15, 2025

Status verified date

Mar, 2026

Completion date

May 15, 2027

Anticipated

Primary completion date

May 15, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Inclusion criterai:

All patients diagnosed from 2000 to 31/12/2026

  • minimum follow-up 6 months
  • Age <18 years at diagnosis;
  • All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable.

Exclusion Criteria:

  • Age ≥18 years at diagnosis;
  • Unwilling to participate into the study;
  • A follow-up period < 6 months.

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Arms

Juvenile eosinophilic fasciitis

Age < 18 years at diagnosis

\- The study will include two different populations:

1. Patients who have received a diagnosis of JEF based on deep fascial biopsy characteristics.
2. Patients who have received a diagnosis of JEF based on typical MRI findings, but without performing a deep fascial biopsy.

Primary outcome measure

  • Clinical and laboratory features [ Time Frame: 2025-2027 ]

Central Contacts and Locations

Central contacts

Locations

University of Alabama at Birmingham

Recruiting

Birmingham, Alabama, United States, 35294

SUNY Upstate Pediatric Rheumatology

Recruiting

Syracuse, New York, United States, 13210

More Information

Sponsor

Meyer Children's Hospital IRCCS

Last update posted

Mar 11, 2026

Last verified

Mar, 2026

Keywords

  • Eosinophilic Fasciitis
  • Juvenile eosinophilic fasciitis
  • juvenile scleroderma
  • sclerosing disorders

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Meyer Children's Hospital IRCCS on 2026-03-11.